Literature DB >> 15582552

Following in vitro activation of mitogen-activated protein kinases by mass spectrometry and tryptic peptide analysis: purifying fully activated p38 mitogen-activated protein kinase alpha.

Anna E Szafranska1, Xuemei Luo, Kevin N Dalby.   

Abstract

p38 mitogen-activated protein kinase alpha (MAPKalpha) belongs to the MAPK subfamily, which plays a pivotal role in cell signal transduction, where it mediates responses to cell stresses and, to a lesser extent, growth factors. Although its cellular function has been under intense scrutiny since its initial discovery, little progress has been made in understanding its kinetic mechanism. A contributory factor has been the lack of a fast and rigorous method for the purification of activated p38 MAPKalpha in sufficient quantity and purity for biophysical studies. Here we present a method for the preparation of milligram quantities of activated p38 MAPKalpha, specifically phosphorylated on Thr180 and Tyr182. Purification of the inactive (unphosphorylated) p38 MAPKalpha is facilitated by an N-terminal hexahistidine tag. Removal of this tag from His6-p38 MAPKalpha, prior to its activation, is essential to ensure preparation of high yields of homogeneous, dually phosphorylated enzyme. Activation is achieved on incubation with a glutathione S-transferase (GST) fusion of the constitutively active mutant of the upstream activator, MKK6b (GST-MKK6b S207E T211E), in the presence of MgATP2-. Notably, we show that specific formation of activated p38 MAPKalpha can be quantified by following the formation of the bis-phosphorylated tryptic peptide, 173-HTDDEMT*GY*VATR-186, using [gamma-32P]adenosine triphosphate (ATP) as the phosphate source and reverse-phase high-performance liquid chromatography (HPLC) to separate the phosphopeptides. This approach offers the only means to specifically determine both stoichiometry and specificity of p38 MAPKalpha phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15582552     DOI: 10.1016/j.ab.2004.09.039

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  6 in total

1.  Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.

Authors:  Ashraf A Aly; Essmat M El-Sheref; Momtaz E M Bakheet; Mai A E Mourad; Stefan Bräse; Mahmoud A A Ibrahim; Martin Nieger; Boyan K Garvalov; Kevin N Dalby; Tamer S Kaoud
Journal:  Bioorg Chem       Date:  2018-10-23       Impact factor: 5.275

2.  Mitogen-activated protein kinase (MAPK) phosphatase 3-mediated cross-talk between MAPKs ERK2 and p38alpha.

Authors:  Yuan-Yuan Zhang; Jia-Wei Wu; Zhi-Xin Wang
Journal:  J Biol Chem       Date:  2011-03-16       Impact factor: 5.157

3.  Activated ERK2 is a monomer in vitro with or without divalent cations and when complexed to the cytoplasmic scaffold PEA-15.

Authors:  Tamer S Kaoud; Ashwini K Devkota; Richard Harris; Mitra S Rana; Olga Abramczyk; Mangalika Warthaka; Sunbae Lee; Mark E Girvin; Austen F Riggs; Kevin N Dalby
Journal:  Biochemistry       Date:  2011-05-04       Impact factor: 3.162

4.  Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration.

Authors:  Tamer S Kaoud; Shreya Mitra; Sunbae Lee; Juliana Taliaferro; Michael Cantrell; Klaus D Linse; Carla L Van Den Berg; Kevin N Dalby
Journal:  ACS Chem Biol       Date:  2011-04-05       Impact factor: 5.100

5.  Structural Basis for the Subversion of MAP Kinase Signaling by an Intrinsically Disordered Parasite Secreted Agonist.

Authors:  Erika Pellegrini; Andrés Palencia; Laurence Braun; Ulrike Kapp; Alexandre Bougdour; Hassan Belrhali; Matthew W Bowler; Mohamed-Ali Hakimi
Journal:  Structure       Date:  2016-11-23       Impact factor: 5.006

6.  Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo.

Authors:  Tamer S Kaoud; William H Johnson; Nancy D Ebelt; Andrea Piserchio; Diana Zamora-Olivares; Sabrina X Van Ravenstein; Jacey R Pridgen; Ramakrishna Edupuganti; Rachel Sammons; Micael Cano; Mangalika Warthaka; Matthew Harger; Clint D J Tavares; Jihyun Park; Mohamed F Radwan; Pengyu Ren; Eric V Anslyn; Kenneth Y Tsai; Ranajeet Ghose; Kevin N Dalby
Journal:  Nat Commun       Date:  2019-11-19       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.